Comorbidities and Adherence: Tailoring mHSPC Treatment

Clinical Brief: Patient-Specific Factors in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Management

Main Discussion Topics

• Beyond Chronological Age: Importance of assessing frailty and performance status using validated scales
• Relevant Comorbidities: Bone density, cardiovascular health, cognitive function, metabolic diseases, and fall risk
• Socioeconomic Considerations: Transportation access, housing status, and caregiver support
• Monitoring Requirements: Regular reassessment of patient status as conditions change over time

Key Points for Physicians

• Proactive monitoring and adjustments are essential to maintain treatment efficacy
• Multidisciplinary care is increasingly important in complex cases
• Consider consultation with cardio-oncology, endocrinology, geriatrics, and bone health specialists
• Treatment optimization is key to enabling patients to remain on therapy and improve outcomes

Notable Insights

The presenter emphasizes that chronological age may not be the best determinant of treatment selection and tolerability, as some 80-year-old patients may be more fit than those 20 years younger.

Clinical Significance

Comprehensive assessment of patient-specific factors beyond disease characteristics is essential for optimizing treatment selection, improving adherence, and maximizing clinical outcomes in metastatic hormone-sensitive prostate cancer.